A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?

被引：27

作者：

Joudi, Maryam ^{[1
]}

Moradi Binabaj, Maryam ^{[2
]}

Porouhan, Pejman ^{[3
]}

PeyroShabany, Babak ^{[4
]}

Tabasi, Mohsen ^{[5
]}

Fazilat-Panah, Danial ^{[6
]}

Khajeh, Mahtab ^{[7
]}

Mehrabian, Arezoo ^{[8
]}

Dehghani, Mansoureh ^{[9
]}

Welsh, James S. ^{[10
,11
]}

Keykhosravi, Batol ^{[7
]}

Akbari Yazdi, Azam ^{[7
]}

Ariamanesh, Mona ^{[12
]}

Ghasemi, Ahmad ^{[13
]}

Ferns, Gordon ^{[14
]}

Javadinia, Seyed Alireza ^{[7
]}

机构：

[1] Zabol Univ Med Sci, Sch Med, Dept Pediat, Zabol, Iran

[2] Sabzevar Univ Med Sci, Cellular & Mol Res Ctr, Sabzevar, Iran

[3] Sabzevar Univ Med Sci, Vasei Hosp, Dept Radiat Oncol, Sabzevar, Iran

[4] Sabzevar Univ Med Sci, Dept Internal Med, Sabzevar, Iran

[5] Temple Univ, Ctr Inflammat & Lung Res, Lewis Katz Sch Med, Philadelphia, PA 19122 USA

[6] Babol Univ Med Sci, Canc Res Ctr, Babol, Iran

[7] Sabzevar Univ Med Sci, Vasei Clin Res Dev Unit, Sabzevar, Iran

[8] Iran Univ Med Sci, Student Res Comm, Tehran, Iran

[9] Neyshabur Univ Med Sci, Dept Radiat Oncol, Neyshabur, Iran

[10] Edward Hines Jr VA Hosp, Dept Radiat Oncol, Chicago, IL USA

[11] Loyola Univ Chicago, Stritch Sch Sci, Chicago, IL USA

[12] Neyshabur Univ Med Sci, Dept Pathol, Neyshabur, Iran

[13] Neyshabur Univ Med Sci, Dept Basic Sci, Neyshabur, Iran

[14] Brighton & Sussex Med Sch, Dept Med Educ, Brighton, E Sussex, England

来源：

FRONTIERS IN ENDOCRINOLOGY | 2022年 / 13卷

关键词：

breast cancer; inactivated SARS-CoV-2 vaccine; seroconversion; SARS-CoV2; COVID-19; vaccine; cancer; malignancy; Iran; IMMUNE-SYSTEM; CHEMOTHERAPY;

D O I：

10.3389/fendo.2022.798975

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

AimTo determine the efficacy and safety of inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer. MethodsIn this multi- institutional cohort study, a total of 160 breast cancer patients (mean age of 50.01 +/- 11.5 years old) were assessed for the SARS-CoV-2 Anti-Spike IgG and SARS-CoV2 Anti RBD IgG by ELISA after two doses of 0.5 mL inactivated, COVID-19 vaccine (BBIBP-CorV). All patients were followed up for three months for clinical COVID-19 infection based on either PCR results or imaging findings. Common Terminology Criteria for Adverse Events were used to assess the side effects. ResultsThe presence of SARS-CoV-2 anti-spike IgG, SARS-CoV2 anti-RBD IgG, or either of these antibodies was 85.7%, 87.4%, and 93.3%. The prevalence of COVID-19 infection after vaccination was 0.7%, 0% and 0% for the first, second and third months of the follow-up period. The most common local and systemic side-effects were injection site pain and fever which were presented in 22.3% and 24.3% of patients, respectively. DiscussionThe inactivated SARS-CoV-2 vaccine (BBIBP-CorV) is a tolerable and effective method to prevent COVID-19.

引用

页数：7

共 48 条

[1] Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling [J].

Alagoz, Oguzhan ;

Lowry, Kathryn P. ;

Kurian, Allison W. ;

Mandelblatt, Jeanne S. ;

Ergun, Mehmet A. ;

Huang, Hui ;

Lee, Sandra J. ;

Schechter, Clyde B. ;

Tosteson, Anna N. A. ;

Miglioretti, Diana L. ;

Trentham-Dietz, Amy ;

Nyante, Sarah J. ;

Kerlikowske, Karla ;

Sprague, Brian L. ;

Stout, Natasha K. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (11) :1484-1494

[2] Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy [J].

Ariamanesh, Mona ;

Porouhan, Pejman ;

PeyroShabany, Babak ;

Fazilat-Panah, Danial ;

Dehghani, Mansoureh ;

Nabavifard, Maryam ;

Hatami, Farbod ;

Fereidouni, Mohammad ;

Welsh, James S. ;

Javadinia, Seyed Alireza .

CANCER INVESTIGATION, 2022, 40 (01) :26-34

[3] Prevalence and clinical characterization of cancer patients with asymptomatic SARS-CoV-2 infection history [J].

Bi, Jianping ;

Lin, Yongping ;

Zhong, Ran ;

Jiang, Guowu ;

Verma, Vivek ;

Shi, Hongwei ;

Li, Jianfu ;

Tong, Xianli ;

Li, Yanping ;

Hu, Desheng ;

Liang, Wenhua ;

Han, Guang ;

He, Jianxing .

JOURNAL OF INFECTION, 2020, 81 (06) :E22-E24

[4] The immune system and response to HER2-targeted treatment in breast cancer [J].

Bianchini, Giampaolo ;

Gianni, Luca .

LANCET ONCOLOGY, 2014, 15 (02) :E58-E68

[5] Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus [J].

Chan, C. M. ;

Tse, Herman ;

Wong, S. S. Y. ;

Woo, P. C. Y. ;

Lau, S. K. P. ;

Chen, L. ;

Zheng, B. J. ;

Huang, J. D. ;

Yuen, K. Y. .

JOURNAL OF CLINICAL VIROLOGY, 2009, 45 (01) :54-60

[6] Cancer Statistics in China, 2015 [J].

Chen, Wanqing ;

Zheng, Rongshou ;

Baade, Peter D. ;

Zhang, Siwei ;

Zeng, Hongmei ;

Bray, Freddie ;

Jemal, Ahmedin ;

Yu, Xue Qin ;

He, Jie .

CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132

[7] Impact of COVID19 pandemic on the hospitalization burden of cancer patients: Results of a quasi-experimental study. [J].

Cristobal Sanchez, Juan ;

Nunez Garcia, Beatriz ;

Ruano, Alberto ;

Blanco, Mariola ;

Cantos Sanchez de Ibarguren, Blanca ;

Mendez, Miriam ;

Jose Ramos-Vegue, Arturo ;

Maria Morito, Ana ;

Aguado, Ramon ;

Provencio-Pulla, Mariano .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[8] Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak [J].

Dai, Mengyuan ;

Liu, Dianbo ;

Liu, Miao ;

Zhou, Fuxiang ;

Li, Guiling ;

Chen, Zhen ;

Zhang, Zhian ;

You, Hua ;

Wu, Meng ;

Zheng, Qichao ;

Xiong, Yong ;

Xiong, Huihua ;

Wang, Chun ;

Chen, Changchun ;

Xiong, Fei ;

Zhang, Yan ;

Peng, Yaqin ;

Ge, Siping ;

Zhen, Bo ;

Yu, Tingting ;

Wang, Ling ;

Wang, Hua ;

Liu, Yu ;

Chen, Yeshan ;

Mei, Junhua ;

Gao, Xiaojia ;

Li, Zhuyan ;

Gan, Lijuan ;

He, Can ;

Li, Zhen ;

Shi, Yuying ;

Qi, Yuwen ;

Yang, Jing ;

Tenen, Daniel G. ;

Chai, Li ;

Mucci, Lorelei A. ;

Santillana, Mauricio ;

Cai, Hongbing .

CANCER DISCOVERY, 2020, 10 (06) :783-791

[9] Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium [J].

Dietz, Jill R. ;

Moran, Meena S. ;

Isakoff, Steven J. ;

Kurtzman, Scott H. ;

Willey, Shawna C. ;

Burstein, Harold J. ;

Bleicher, Richard J. ;

Lyons, Janice A. ;

Sarantou, Terry ;

Baron, Paul L. ;

Stevens, Randy E. ;

Boolbol, Susan K. ;

Anderson, Benjamin O. ;

Shulman, Lawrence N. ;

Gradishar, William J. ;

Monticciolo, Debra L. ;

Plecha, Donna M. ;

Nelson, Heidi ;

Yao, Katharine A. .

BREAST CANCER RESEARCH AND TREATMENT, 2020, 181 (03) :487-497

[10] Medical care disruptions during the first six months of the COVID-19 pandemic: the experience of older breast cancer survivors [J].

Dilawari, A. ;

Rentscher, K. E. ;

Zhai, W. ;

Zhou, X. ;

Ahles, T. A. ;

Ahn, J. ;

Bethea, T. N. ;

Carroll, J. E. ;

Cohen, H. J. ;

Graham, D. A. ;

Jim, H. S. L. ;

McDonald, B. ;

Nakamura, Z. M. ;

Patel, S. K. ;

Root, J. C. ;

Small, B. J. ;

Saykin, A. J. ;

Tometich, D. ;

Van Dyk, K. ;

Mandelblatt, J. S. .

BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (02) :287-293

← 1 2 3 4 5 →